NASDAQ:ATNF 180 Life Sciences (ATNF) Stock Price, News & Analysis $3.58 +0.22 (+6.55%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$3.50 -0.09 (-2.37%) As of 08:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About 180 Life Sciences Stock (NASDAQ:ATNF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get 180 Life Sciences alerts:Sign Up Key Stats Today's Range$3.09▼$3.7150-Day Range$0.80▼$3.5852-Week Range$0.66▼$17.75Volume812,363 shsAverage Volume7.03 million shsMarket Capitalization$21.62 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview 180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California. Read More 180 Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks12th Percentile Overall ScoreATNF MarketRank™: 180 Life Sciences scored higher than 12% of companies evaluated by MarketBeat, and ranked 877th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for 180 Life Sciences. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of 180 Life Sciences is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 180 Life Sciences is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio180 Life Sciences has a P/B Ratio of 4.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about 180 Life Sciences' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.89% of the float of 180 Life Sciences has been sold short.Short Interest Ratio / Days to Cover180 Life Sciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in 180 Life Sciences has recently decreased by 0.31%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend Yield180 Life Sciences does not currently pay a dividend.Dividend Growth180 Life Sciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.89% of the float of 180 Life Sciences has been sold short.Short Interest Ratio / Days to Cover180 Life Sciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in 180 Life Sciences has recently decreased by 0.31%, indicating that investor sentiment is improving. News and Social Media1.1 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for 180 Life Sciences this week, compared to 0 articles on an average week.Search Interest11 people have searched for ATNF on MarketBeat in the last 30 days. This is an increase of 1,000% compared to the previous 30 days.MarketBeat Follows2 people have added 180 Life Sciences to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, 180 Life Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders38.20% of the stock of 180 Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 4.07% of the stock of 180 Life Sciences is held by institutions.Read more about 180 Life Sciences' insider trading history. Receive ATNF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 180 Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address ATNF Stock News Headlines180 Life Sciences rises after raising $425 million for Ethereum strategyAugust 6 at 2:20 AM | au.investing.com180 Life Sciences Closes $425 Million Private Placement to Advance its Ethereum Treasury StrategyAugust 4 at 10:30 PM | prnewswire.comWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.August 7 at 2:00 AM | Priority Gold (Ad)180 Life Sciences (NASDAQ:ATNF) Earns "Sell (E+)" Rating from Weiss RatingsJuly 31, 2025 | americanbankingnews.com180 Life Sciences Announce an Upsized $425 Million Private Placement to Establish an Ether Treasury Reserve Led by Consortium of Digital Asset Leaders to Launch ETHZillaJuly 29, 2025 | prnewswire.com180 Life Sciences Corp. (ATNF) Latest Press Releases - Seeking AlphaJuly 2, 2025 | seekingalpha.com180 Life Sciences Earnings Estimates, EPS & Revenue | NASDAQ:ATNF | BenzingaApril 21, 2025 | benzinga.com180 Life Sciences Corp. modifies former CEO's exit termsFebruary 8, 2025 | msn.comSee More Headlines ATNF Stock Analysis - Frequently Asked Questions How have ATNF shares performed this year? 180 Life Sciences' stock was trading at $1.82 at the beginning of 2025. Since then, ATNF shares have increased by 96.7% and is now trading at $3.58. How were 180 Life Sciences' earnings last quarter? 180 Life Sciences Corp. (NASDAQ:ATNF) posted its earnings results on Wednesday, July, 23rd. The company reported ($0.30) earnings per share (EPS) for the quarter. When did 180 Life Sciences' stock split? 180 Life Sciences's stock reverse split on Wednesday, February 28th 2024.The 1-19 reverse split was announced on Wednesday, February 28th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 28th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of 180 Life Sciences? Shares of ATNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of 180 Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that 180 Life Sciences investors own include Meta Platforms (META), NIO (NIO), Enterprise Products Partners (EPD), HubSpot (HUBS), Netflix (NFLX), Plug Power (PLUG). Company Calendar Last Earnings7/23/2025Today8/07/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ATNF CIK1690080 Webwww.kblmerger.com Phone(650) 507-0669FaxN/AEmployees7Year FoundedN/AProfitability EPS (Trailing Twelve Months)($15.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$6.17 million Net MarginsN/A Pretax MarginN/A Return on Equity-141.25% Return on Assets-80.77% Debt Debt-to-Equity RatioN/A Current Ratio0.58 Quick Ratio0.58 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.89 per share Price / Book4.02Miscellaneous Outstanding Shares6,040,000Free Float3,732,000Market Cap$21.62 million OptionableNo Data Beta0.38 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:ATNF) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredWall Street Hates This Gold IRA Strategy—Here’s WhyWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 180 Life Sciences Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share 180 Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.